Acknowledgments

The authors are supported by grants from the Leukemia Lymphoma Society (VK, SN), the NIH P01 CA05826 (CCPP) (SN), and the Rosemary Breslin Research fund. The authors thank Heather Hewitt and Ellie Park, for assisting in the preparation of this work, our colleagues at Memorial Sloan-Kettering Cancer Center, and the Myelodysplastic Syndrome Foundation.

7. Telfer PT, et al.: Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major. Br J Haematol 110(4):971-977, 2000.

8. Olivieri NF, et al.: Survival in medically treated patients with homozygous beta-thalassemia. N Engl J Med 331(9):574-578, 1994.

9. Dodd RY, Notari EPt, Stramer SL: Current prevalence and incidence of infectious disease markers and estimated window-period risk in the American Red Cross blood donor population. Transfusion 42(8):975-979, 2002.

10. West Nile Virus Viremic Blood Donor Activity in the United States (reported to CDC as of September 21, 2004). Available at: http://www.cdc.gov/ncidod/dvbid/west-nile/surv&control104Maps_Viremic.htm

11. Hellstrom-Lindberg E: Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 89(1):67-71, 1995.

12. Aoki I, et al.: Responsiveness of bone marrow erythropoietic stem cells (CFU-E and BFU-E) to recombinant human erythropoietin (rh-Ep) in vitro in aplastic anemia and myelodysplastic syndrome. Am J Hematol 35(1)16-12, 1990.

13. Jacobs A, et al.: Circulating erythropoietin in patients with myelodysplastic syndromes. Br J Haematol 73(1):36-39, 1989.

14. Casadevall N: Update on the role of epoetin alfa in hematologic malignancies and myelodysplastic syndromes. Semin Oncol 25(3 suppl 7):12-18, 1998.

15. Anonymous: A randomized double-blind placebo-controlled study with subcutaneous recombinant human erythropoietin in patients with low-risk myelodysplastic syndromes. Italian Cooperative Study Group for rHuEpo in Myelodysplastic Syndromes.

Br J Haematol 103(4):1070-1074, 1998.

16. Bennett CL, et al.: Pure red-cell aplasia and epoetin therapy. N Engl J Med 351(14):1403-1408, 2004.

17. Harmenberg J, Hoglund M, Hellstrom-Lindberg E:

G- and GM-CSF in oncology and oncological haematol-ogy. Eur J Haematol Suppl 55:1-28, 1994.

18. Greenberg P, et al.: Phase III randomized multicenter trial of G-CSF vs. observation for myelodysplastic syndromes (MDS). Blood 82(suppl 1):196a, 1993.

19. Willemze R, et al.: A randomized phase-I/II multicenter study of recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF) therapy for patients with myelodysplastic syndromes and a relatively low risk of acute leukemia. EORTC Leukemia Cooperative Group. Ann Hematol 64(4):173-180, 1992.

20. Schuster MW, et al.: Granulocyte-macrophage colony-stimulating factor (GM-CSF) for myelodysplastic syndrome (MDS): results of a multi-center randomized trial. Blood 76:318a, 1990.

21. Hellstrom-Lindberg E, et al.: Treatment of anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomized phase II study and long-term follow-up of 71 patients. Blood 92(1):68-75, 1998.

22. Negrin RS, et al.: Treatment of the anemia of myelodys-plastic syndromes using recombinant human granulo-cyte colony-stimulating factor in combination with ery-thropoietin. Blood 82(3):737-743, 1993.

23. Negrin RS, et al.: Maintenance treatment of the anemia of myelodysplastic syndromes with recombinant human granulocyte colony-stimulating factor and erythropoietin: evidence for in vivo synergy. Blood 87(10):4076-4081, 1996.

24. Remacha AF, et al.: Erythropoietin plus granulocyte colony-stimulating factor in the treatment of myelodys-plastic syndromes. Identification of a subgroup of responders. The Spanish Erythropathology Group. Haematologica 84(12):1058-1064, 1999.

25. Hellstrom-Lindberg E, et al.: Erythroid response to treatment with G-CSF plus erythropoietin for the anaemia of patients with myelodysplastic syndromes: proposal for a predictive model. Br J Haematol 99(2):344-351, 1997.

26. Casadevall N, et al.: Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trial. Blood 104(2):321-327, 2004.

27. Thompson JA, et al.: Effect of recombinant human ery-thropoietin combined with granulocyte/macrophage colony-stimulating factor in the treatment of patients with myelodysplastic syndrome. GM/EPO MDS Study Group. Blood 95(4):1175-1179, 2000.

28. D'Amato RJ, et al.: Thalidomide is an inhibitor of angio-genesis. Proc Natl Acad Sci USA 91(9):4082-4085, 1994.

29. Moreira AL, et al.: Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation. / Exp Med 177(6):1675-1680, 1993.

30. Singhal S, et al.: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 341(21): 1565-1571, 1999.

31. Raza A, et al.: Thalidomide produces transfusion independence in long-standing refractory anemias of patients with myelodysplastic syndromes. Blood 98(4):958-965, 2001.

32. List AF, et al.: Efficacy and safety of CC5013 for treatment of anemia in patients with myelodysplastic syndromes (MDS) [abstract]. Blood 102(11):184a, 2003. Abstract 641.

33. Biesma DH, van den Tweel JG, Verdonck LF: Immunosuppressive therapy for hypoplastic myelodysplastic syndrome. Cancer 79(8):1548-1551, 1997.

34. Molldrem JJ, et al.: Antithymocyte globulin for patients with myelodysplastic syndrome. Br J Haematol 99(3): 699-705, 1997.

35. Saunthararajah Y, et al.: HLA-DR15 (DR2) is overrepre-sented in myelodysplastic syndrome and aplastic anemia and predicts a response to immunosuppression in myelodysplastic syndrome. Blood 100(5):1570-1574, 2002.

36. Catalano L, et al.: Prolonged response to cyclosporin-A in hypoplastic refractory anemia and correlation with in vitro studies. Haematologica 85(2):133-138, 2000.

37. Jonasova A, et al.: Cyclosporin A therapy in hypoplastic MDS patients and certain refractory anaemias without hypoplastic bone marrow. Br J Haematol 100(2):304-309, 1998.

38. List AF, et al.: Stimulation of hematopoiesis by amifos-tine in patients with myelodysplastic syndrome. Blood 90(9):3364-3369, 1997.

39. Bowen DT, et al.: Poor response rate to a continuous schedule of Amifostine therapy for 'low/intermediate risk' myelodysplastic patients. Br J Haematol 103(3): 785-787, 1998.

40. Invernizzi R, et al.: Clinical and biological effects of treatment with amifostine in myelodysplastic syndromes. Br J Haematol 118(1):246-250, 2002.

41. Grossi A, et al.: Amifostine in the treatment of low-risk myelodysplastic syndromes. Haematologica 85(4): 367-371, 2000.

42. Raza A, et al.: Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxi-fylline, and ciprofloxacin with or without dexametha-sone. Blood 95(5):1580-1587, 2000.

43. List AF, et al.: Arsenic trioxide in patients with myelodysplastic syndromes (MDS): preliminary results of a phase II clinical study [abstract]. J Clin Oncol 22(14S), 2004. Abstract 6512.

44. Vey N, et al.: TrisenoxTM (arsenic trioxide) in patients with myelodysplastic syndromes (MDS): preliminary results of a phase I/II study [abstract]. In: Abstracts and Program of the 9th Congress of the European Hematology Association, 2004 June 10-13(. Abstract #467.

45. Raza A, et al.: Arsenic trioxide and thalidomide combination produces multi-lineage hematological responses in myelodysplastic syndromes patients, particularly in those with high pre-therapy EVI1 expression. Leuk Res 28(8):791-803, 2004.

46. Morosetti R, Koeffler HP: Differentiation therapy in myelodysplastic syndromes. Semin Hematol 33(3): 236-245, 1996.

47. Miller KB, et al.: The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phaseIII intergroup study. Ann Hematol 65(4):162-168, 1992.

48. Koeffler HP, et al.: Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disorders. Blood 71(3):703-708, 1988.

49. Mellibovsky L, et al.: Vitamin D treatment in myelodysplastic syndromes. Br J Haematol 100(3):516-520, 1998.

50. Jones PA, Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell 20(1):85-93, 1980.

51. Silverman LR, et al.: Effects of treatment with 5-azacyti-dine on the in vivo and in vitro hematopoiesis in patients with myelodysplastic syndromes. Leukemia 7 (suppl 1): 21-29, 1993.

52. Silverman LR, Holland JC, et al.: Azacytidine (azaC) in myelodysplastic syndromes (MDS), CALGB studies 8421 and 8921 (abstract). Ann Hematol 68(suppl 1):12a, 1994.

53. Silverman LR, et al.: Randomized controlled trial of azac-itidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20(10):2429-2440, 2002.

54. Kornblith AB, et al.: Impact of azacytidine on the quality of life of patients with myelodysplastic syndrome treated in a randomized phase III trial: a Cancer and Leukemia Group B study. J Clin Oncol 20(10):2441-2452, 2002.

55. Wijermans PW, Luebbert M, Verhoef G: Low dose Decitabine for elderly high risk MDS patients: who will respond? [abstract] Blood 100(11):96a, 2002. Abstract 355.

56. van denBosch J, et al.: The effects of 5-aza-2'-deoxycyti-dine (Decitabine) on the platelet count in patients with intermediate and high-risk myelodysplastic syndromes. Leuk Res 28(8):785-790, 2004.

57. Saba H, et al.: First report of the phase III North American trial of Dectabine in advanced myelodysplas-tic syndrome (MDS) [abstract]. Blood 104(11):23a, 2004. Abstract 67.

58. Cheng JC, et al.: Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J Natl Cancer Inst 95(5):399-409, 2003.

59. Beran M, et al.: Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia. Leuk Lymphoma 31(5-6):521-531, 1998.

60. Beran M, et al.: Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol 17(9):2819-2830, 1999.

This page intentionally left blank

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment